WO1996009075A1 - Procede de traitement d'affections malignes - Google Patents
Procede de traitement d'affections malignes Download PDFInfo
- Publication number
- WO1996009075A1 WO1996009075A1 PCT/RU1995/000195 RU9500195W WO9609075A1 WO 1996009075 A1 WO1996009075 A1 WO 1996009075A1 RU 9500195 W RU9500195 W RU 9500195W WO 9609075 A1 WO9609075 A1 WO 9609075A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- days
- month
- day
- drug
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 18
- 230000003211 malignant effect Effects 0.000 title abstract 2
- 230000002285 radioactive effect Effects 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims 2
- 230000000771 oncological effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 2
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 150000002506 iron compounds Chemical class 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 231100001261 hazardous Toxicity 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000002901 radioactive waste Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1258—Pills, tablets, lozenges
Definitions
- the task posed is solved in that, in the case of the use of an easy-to-sing, in addition to the introduction of a radioactive nuclide 59 Ges with an induced activity of 0.8 mcg for a single dose of the drug, a safe preparation, is administered once a day after a month of treatment, after a month of treatment
- a weekly annual supply (GWP) for 59GH is made
- Diagnosis is an immune disease with a temporal lobe of the lower brain. A thorough treatment has been made. for the course of ceremonies, radiation therapy for the main brain of the SDS 44 g. ⁇ connection ⁇ g ⁇ essi ⁇ vaniem ⁇ ezni, ⁇ azheniem ⁇ av ⁇ y gemis ⁇ e ⁇ y and zadneg ⁇ ⁇ ga ⁇ v ⁇ g ⁇ zhelud ⁇ ch ⁇ a, nacha ⁇ treatment ⁇ adi ⁇ a ⁇ ivnym nu ⁇ id ⁇ m 59 Ge, navedenn ⁇ y a ⁇ ivn ⁇ s ⁇ yu 0.8 m ⁇ i on ⁇ dnu d ⁇ zu ⁇ e ⁇ a ⁇ a ⁇ a ⁇ s ⁇ eme ⁇ echeniya, ⁇ isann ⁇ y in ⁇ ime ⁇ e ⁇ .
- Diagnosis disease ⁇ 4 ⁇ 0 ⁇ 0.
- the company could not be removed due to the widespread process.
- the treatment was carried out 59 G with an induced activity of 0.8 mg for one dose of the drug at the time of treatment described in the case of ⁇ .
- the treatment must be stopped at the last end of the course of the first course of treatment. Conducted - removal of the kidney.
- After two months 8 For information on the subject of publication, please refer to the scheme described in this article. After a year, it is a good condition that it is in good condition.
- Diagnosis Esophagus ⁇ .
- This product is intended for use in the care of children, as well as small arms, food, handicap and other. Treatment with this method can be produced as it is, both alone and in combination with well-known methods of the treatment of the drug. Taking into account
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Le procédé proposé de traitement d'affections malignes consiste à utiliser un nucléide radioactif Fe59 présentant une activité induite de 0,8 mCi par dose de la préparation sous forme de comprimé, 50 comprimés étant absorbés pendant une durée de six mois. Le traitement de l'invention est appliqué soit indépendamment soit simultanément avec d'autres procédés de traitement du cancer. Etant donné que les cellules tumorales tendent à accumuler des composés de fer, le radionucléide Fe59, d'une activité induite de 0,8 mCi par dose, peut être utilisé en tant qu'agent de diagnostic en cancérologie.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU34882/95A AU3488295A (en) | 1994-09-21 | 1995-09-04 | Method of treating malignant conditions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU94035764 | 1994-09-21 | ||
RU94035764A RU2053776C1 (ru) | 1994-09-21 | 1994-09-21 | Способ лечения онкологического заболевания |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996009075A1 true WO1996009075A1 (fr) | 1996-03-28 |
Family
ID=20160826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU1995/000195 WO1996009075A1 (fr) | 1994-09-21 | 1995-09-04 | Procede de traitement d'affections malignes |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU3488295A (fr) |
RU (1) | RU2053776C1 (fr) |
WO (1) | WO1996009075A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2153334C2 (ru) * | 1998-10-16 | 2000-07-27 | Хокси Дин Корнелиус | Способ лечения онкологического заболевания |
RU2193866C2 (ru) * | 1999-07-19 | 2002-12-10 | Новосибирский научно-исследовательский институт травматологии и ортопедии | Способ оперативного доступа при удалении менингиомы спинного мозга |
RU2153358C1 (ru) * | 1999-11-10 | 2000-07-27 | Центральный научно-исследовательский рентгенорадиологический институт МЗ России | Способ лечения остеолитических метастазов |
RU2174015C1 (ru) * | 2000-11-21 | 2001-09-27 | Кешелава Виктор Владимирович | Препарат для лечения онкологического заболевания, способ его получения и применение |
RU2182022C1 (ru) * | 2001-05-24 | 2002-05-10 | Российская медицинская академия последипломного образования МЗ РФ | Способ лечения онкологических заболеваний щитовидной железы |
RU2280407C2 (ru) * | 2004-06-24 | 2006-07-27 | Виктор Владимирович Кешелава | Способ диагностики и лечения мастопатии |
RU2271831C1 (ru) * | 2004-07-19 | 2006-03-20 | Виктор Владимирович Кешелава | Способ лечения онкологических заболеваний |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4898724A (en) * | 1984-06-04 | 1990-02-06 | The Dow Chemical Company | Organis amine phosphonic acid complexes for the treatment of calcific tumors |
US5006329A (en) * | 1988-01-22 | 1991-04-09 | Cadema Medical Products, Inc. | Radioactive tagged compounds and method for the treatment of metastatic bone cancer |
WO1991016075A1 (fr) * | 1990-04-20 | 1991-10-31 | Australian Nuclear Science & Technology Organisation | Techniques de traitement de la moelle osseuse |
WO1993000927A1 (fr) * | 1991-07-12 | 1993-01-21 | Antisoma Limited | Traitement du cancer |
WO1994004189A1 (fr) * | 1992-08-25 | 1994-03-03 | Medac Gesellschaft Fur Klinische Spezialpräparate Mbh | Anticorps/radio-isotope conjugues de diagnostic et/ou therapie de tumeurs |
-
1994
- 1994-09-21 RU RU94035764A patent/RU2053776C1/ru active
-
1995
- 1995-09-04 WO PCT/RU1995/000195 patent/WO1996009075A1/fr active Application Filing
- 1995-09-04 AU AU34882/95A patent/AU3488295A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4898724A (en) * | 1984-06-04 | 1990-02-06 | The Dow Chemical Company | Organis amine phosphonic acid complexes for the treatment of calcific tumors |
US5006329A (en) * | 1988-01-22 | 1991-04-09 | Cadema Medical Products, Inc. | Radioactive tagged compounds and method for the treatment of metastatic bone cancer |
WO1991016075A1 (fr) * | 1990-04-20 | 1991-10-31 | Australian Nuclear Science & Technology Organisation | Techniques de traitement de la moelle osseuse |
WO1993000927A1 (fr) * | 1991-07-12 | 1993-01-21 | Antisoma Limited | Traitement du cancer |
WO1994004189A1 (fr) * | 1992-08-25 | 1994-03-03 | Medac Gesellschaft Fur Klinische Spezialpräparate Mbh | Anticorps/radio-isotope conjugues de diagnostic et/ou therapie de tumeurs |
Also Published As
Publication number | Publication date |
---|---|
RU94035764A (ru) | 1997-03-27 |
RU2053776C1 (ru) | 1996-02-10 |
AU3488295A (en) | 1996-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Becker | One century of radon therapy | |
Nakayama et al. | The history of multimodal treatment of Wilms’ tumor | |
Wowra et al. | Incidence of late radiation necrosis with transient mass effect after interstitial low dose rate radiotherapy for cerebral gliomas | |
Nielsen et al. | Influence of thermotolerance on the interaction between hyperthermia and radiation in a solid tumour in vivo | |
WO1996009075A1 (fr) | Procede de traitement d'affections malignes | |
Wang et al. | Evaluation of endoscopic-ultrasound-guided celiac ganglion irradiation with iodine-125 seeds: a pilot study in a porcine model | |
Juillard et al. | A phase I study of active specific intralymphatic immunotherapy (ASILI) | |
Kjaer | Misteltoe (Iscador) Therapy in Stage Iv Renal Adenocarcinoma: A Phase II study in patients with measurable lung metastases | |
Early et al. | Use of therapeutic radionuclides in medicine | |
WO1992013563A1 (fr) | Preparation antitumorale et son procede de production | |
Fleck et al. | Coccidian-like nature of Toxoplasma gondii | |
Bidin et al. | The ruqyah syar’iyyah verses as a breast cancer therapy: a preliminary evaluation on breast cancer cell line Michigan cancer foundation (MCF-7) | |
Morgan | Fast neutron therapy | |
RU2197301C2 (ru) | Способ лечения больных циррозом печени и хроническим гепатитом и магнитотерапевтическое устройство для его осуществления | |
Biese | Cancer Vaccines Are a'Marvel' | |
Green et al. | Radiotherapy: its nature 6 | |
Philpott et al. | Magnet Therapy: The Self-Help Guide to Magnets-Clinically Proven to Relieve 35 Health Problems | |
WO2002041923A1 (fr) | Preparation destinee au traitement d'une affection oncologique et procedes de fabrication et d'application | |
Donev et al. | Professor Anastas Kocarev, First Macedonian Oncologist with Worldwide Reputation and Pioneer in Cancer Diagnostics and Treatment with Radium. | |
Cassady | Keynote address: Contributions of pediatric oncology: Examples derived from advances made in the treatment of rhabdomyosarcoma and neuroblastoma | |
RU2163811C1 (ru) | Способ лечения рака iii-iv стадии | |
DeVita | Cancer Treatment | |
Priestman | Coping with Radiotherapy | |
Robbins | Radioiodine in the treatment of thyrotoxicosis | |
Hobohm | Healing Heat-an essay on cancer fever therapy: Immunological basics and practical application with 16 case reports |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NO NZ PL PT RO RU SD SE SK UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |